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of amputation. In clinical studies the effectiveness of Hy-
perbaric oxygene therapy of diabetic foot lesion was
proved. Hyperbaric oxygene therapy adjunctive to ther-
apy of diabetic food lesion can reduce anaerobic infec-
tions, improve blood supply and decrease ischemic dam-
age to nerves.
OBJECTIVE: This analysis centred around which of the
alternative therapies-standard therapy plus Hyperbaric
oxygene therapy and standard therapy alone-incurs the
best cost-effectiveness ratio. The comparison of costs and
benefits was made on the basis of a cost-effectiveness
analysis.
METHODS: A decision tree with four endpoints was
constructed: (1) successful therapy without amputations,
(2) small amputations, (3) major amputations with post
hospital treatment, and (4) major amputation with do-
mestic nursing. Data regarding the number and severity
of amputations underlying were taken from a clinical
study. Health care costs included in the model were all
medical costs (hospitalisation, surgical intervention, drug
costs, etc.) and indirect costs (absence from workplace,
retirement). The effectiveness was defined as avoided ma-
jor amputation. The following effectiveness rates were re-
vealed in the clinical study: population with adjunctive
Hyperbaric oxygene therapy, 0.9143; population only
with standard therapy, 0.6666. To improve the robust-
ness of the model, a sensitivity analysis was performed to
determine the influence of the efficacy on the incremental
cost-effectiveness ratio and the effects of of the costs of
post hospital treatment based on the incremental cost-
effectiveness ratio.
RESULTS: Standard therapy plus hyperbaric oxygene
therapy resulted in total costs of DM 45,141.00 per suc-
cessfully treated patient; standard therapy incurred total
costs of DM 52,392.00 per successfully treated patient.
CONCLUSION: The decision tree analysis reveals that
the treatment of diabetic foot lesion with adjunctive Hy-
perbaric oxygene therapy has the best incremental cost-
effectiveness ratio.
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An estimated 8 million people in the U.S. have type II dia-
betes mellitus but are unaware of it.
OBJECTIVES: The study investigated the cost-effective-
ness of early detection of type II diabetes mellitus in vari-
ous risk groups.
METHODS: A Markov model was constructed based on
a societal perspective. There were 4 stages in the model:
(1) unknown diabetes status; (2) alive with diagnosed di-
abetes; (3) alive with diagnosed diabetes and related com-
plications, namely, retinopathy, blindness, neuropathy,
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end-state renal disease, lower leg amputations, circula-
tory disorders; and (4) die secondary to diabetes or its
complications. Individuals could transit from one state to
another annually as a function of the predicted risk fac-
tors from epidemiological studies. The model assumed
that the patients who were screened positive for diabetes
and received treatment would have reduced rate of re-
lated complications as observed in the Diabetes Control
and Complications Trial. Health care costs included in
the model were screening tests, diabetes treatment cost,
complications and death. Various screening test thresh-
olds have also been considered in the model analysis.
RESULTS: Diabetes screening of the entire nonpregnant
adult US population yielded a cost-effectiveness ratio of
$24,600 per quality-adjusted life year. The cost-effective-
ness of screening only extremely obese patients with a
family history of diabetes was $10,083 per quality-
adjusted life year.
CONCLUSIONS: The study suggested that active screen-
ing for type II diabetes mellitus in high-risk individuals
was cost-effective. More information on the actual clini-
cal outcomes for oral diabetes medications is needed to
establish the precision of these estimates.
PGDS
PREDICTING HOSPITALIZATION OF PATIENTS
WITH DIABETES MELLITUS: AN APPLICATION
OF THE BAYESIAN DISCRIMINANT ANALYSIS
Bhattacharyya S
Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA
OBJECTIVE: The main objectives of this paper were to
develop and subsequently test a Bayesian discrimination
model for the purpose of identifying both the personal
and the health care system characteristics predictive of
hospitalization for the treatment of diabetes or commonly
observed comorbidities associated with the disease,
METHODS: First, a Bayesian classification framework
was proposed to discriminate patients into two groups-
the high risk and the low risk. The model was then tested
by using a logit regression technique in order to estimate
the probability of one or more hospitalization events
among diabetes patients. The study used claims data ex-
tracted from the Hawaii Medical Service Association
(HMSA) Private Business Claims (PBS) files for the calen-
dar year 1995. Patients under 65 years were identified by
paid claims with ICD-9-CM diagnosis codes of 250.xx
which gave a sample size of 6,841.
RESULTS: Age, gender, various pharmacotherapy vari-
ables, presence of hypertension, hyperlipidemia, coronary
heart failure, multiple cardiovascular diseases, any com-
bination of commonly observed comorbidities, dialysis
services, and annual eye examination were highly predic-
tive of one or more hospitalization events. The model
showed a predictive power of almost 90%.
CONCLUSION: Multivariate discriminant analysis using a
logit regression model successfully (1) identified important
explanatory variables predictive of hospitalization, (2) as-
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signed patients into one of two mutually exclusive classes,
and (3) offered a benchmark for a comprehensive disease
management strategy for more involved diabetic patients.
PGD6
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There is little published on the relative costs of treatments
in psoriasis.
OBJECTIVE: This study was designed to assess patterns
of medication use, costs, and health care resource utiliza-
tion among US managed care psoriasis patients.
METHODS: Members of 4 HMOs were identified using
pharmacy outpatient and hospital claims data for a
1-year period. Patients were selected if they had (l) at
least 2 claims for psoriasis (lCD-9 code 696, 696.1, and!
or 696.8) or (2) 1 claim for psoriasis and 1 claim for a
psoriasis drug or phototherapy. Descriptive data were
collected to determine psoriasis drug and therapy use,
and total and psoriasis-specific costs.
RESULTS: There were 2,868 members with psoriasis
identified. The data showed that 47.4% of the patients
were on monotherapy and 45% of the patients were on
poly therapy, defined as two or more of the psoriasis-spe-
cific drugs or therapies. This coincides with recent market
evaluations of psoriasis therapies. Topical corticosteroids
were used by 82 % of the patients. Claims for photo-
chemotherapy were made by 9% of members. Eighty per-
cent of patients received therapy from a dermatologist.
There were psoriasis-related hospitalizations for 11 % of
the patients. The median costs for psoriasis-related hospi-
talizations/patient were $252-$1,383 (range: $40-$18,933).
Median total psoriasis-related costs/patient were $155-$170
(range: $0-$24,334).
CONCLUSION: High potency topical corticosteroids re-
main the most commonly used medications for psoriasis.
Even though few patients were hospitalized for psoriasis,
the high costs of hospitalization made it one of the cost
drivers of this condition. Phototherapy procedures, office
visits for non-psoriasis-specific diagnoses, and total drug
costs for psoriasis were additional cost drivers of psoria-
sis treatment.
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CONSEQUENCES OF HIGH HEMATOCRIT
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PATIENTS.
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EPO was approved for the treatment of anemia in renal
dialysis patients in 1989. In 1991, Medicare changed the
way it reimbursed for EPO, and, in response, there was
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an increase in average EPO dosages from 2,793 units to
3,200 units in the six-month period following the policy
change. This change, while meant to improve apparently
low EPO dosing, may have had the unintended conse-
quence of maintaining some patients at unnecessarily
high hematocrit levels. These patients may experience
problems associated with relatively high hernatocrits.
Thus, while some patients may have received too little
EPO prior to the policy change, now they may be receiv-
ing too much. Another recent change in EPO reimburse-
ment policy indicates this may be the case. After July 1,
1997 Medicare will reimburse EPO based on a 90-day
rolling average hematocrit measurement. If the average is
above 36.5%, Medicare will not pay for the EPO. This
policy implicitly assumes that high hematocrit levels are
directly related to inappropriately high doses of EPO.
OBJECTIVE: The purpose of this study is to examine the
incidence of complications resulting from abnormally
high hematocrits, such as vascular shunt thrombosis,
among patients with End-Stage Renal Disease (ESRD).
METHODS: This study uses data from the United States
Renal Data System (USRDS) and logistic regression to
model the incidence of adverse events as a function of he-
matocrit level while controlling for confounding factors
such as age, gender, ethnicity, weight, comorbidities, facil-
ity characteristics, dialysis modality, and dialysis history.
RESULTS: Preliminary results suggest that the incidence
of VST has increased since 1991.
CONCLUSION: This study provides Medicare with in-
formation concerning the appropriateness of the 36.5%
cutoff and the projected impact of the change in reim-
bursement.
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Large national claims databases are sources of vital infor-
mation concerning health care resource utilization. How-
ever, the comparability of data obtained from such data-
bases has not yet been ascertained.
OBJECTIVE: To compare prevalence rates of low back
disorders obtained from two large national inpatient
claims databases and to study variations in length of stay
and corresponding costs.
METHODS: Data were obtained from two independent
databases with inpatient claims information including
ICD-9 codes for specific diagnoses, demographics, length
of stay (LOS), and payments or charges made. One of the
databases is a 20% national inpatient sample of all com-
munity hospitals in the U.S. (HCUP). The other national
database consists of data gathered for privately insured
population (MarketScan). Claims for specific diagnoses
of low back disorders (ICD-9 codes: 720.0-724.9) for
1994 were obtained. Using age, gender, and diagnosis-
